Abstract
The trends and prevalence of antimicrobial susceptibility of pathogens vary by country,
region, and time. Long-term regular surveillance is required to investigate trends
in the antimicrobial resistance of various isolated bacterial pathogens. We report
the results of a nationwide surveillance on the antimicrobial susceptibility of bacterial
respiratory pathogens in Japan conducted by the Japanese Society of Chemotherapy,
the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical
Microbiology. The isolates were collected from clinical specimens obtained from adult
patients who visited a collaborating medical facility between June 2019 and December
2020 and were diagnosed with respiratory tract infections by a physician. Antimicrobial
susceptibility testing was performed in a centralized laboratory according to the
methods recommended by the Clinical and Laboratory Standards Institute.
Susceptibility testing was performed for 932 strains (201 Staphylococcus aureus, 158 Streptococcus pneumoniae, 6 S. pyogenes, 136 Haemophilus influenzae, 127 Moraxella catarrhalis, 141 Klebsiella pneumoniae, and 163 Pseudomonas aeruginosa) collected from 32 facilities in Japan. The proportions of methicillin-resistant
S. aureus and penicillin-resistant S. pneumoniae were 35.3% and 0%, respectively. In H. influenzae, 16.2% and 16.9% were β-lactamase-producing ampicillin resistant and β-lactamase-negative
ampicillin resistant, respectively. Extended-spectrum β-lactamase-producing K. pneumoniae accounted for 5.0% of all K. pneumoniae infections. Carbapenemase-producing K. pneumoniae and multi-drug-resistant P. aeruginosa with metallo-β-lactamase were not detected in this study. This surveillance will
be a useful reference for treating respiratory infections in Japan and will provide
evidence to enhance the appropriate use of antimicrobial agents.
Keywords
Abbreviations:
MSSA (methicillin-susceptible Staphylococcus aureus), PSSP (penicillin-susceptible Streptococcus pneumoniae), PISP (penicillin-intermediate resistant Streptococcus pneumoniae)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Infection and ChemotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global action plan on antimicrobial resistance.2015 (cite 2022 Nov 9])
- The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility.J Infect Chemother. 2008; 14: 279-290
- Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: general view of the pathogens' antibacterial susceptibility.J Infect Chemother. 2015; 21: 410-420
- Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012: general view of the pathogens' antibacterial susceptibility.J Infect Chemother. 2017; 23: 587-597
- Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for clinical microbiology in 2014: general view of the pathogens' antibacterial susceptibility.J Infect Chemother. 2019; 25: 657-668
- Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese society of chemotherapy, the Japanese association for infectious diseases, and the Japanese society for clinical microbiology in 2016: general view of the pathogens' antibacterial susceptibility.J Infect Chemother. 2020; 26: 873-881
- Wayne P.A. Clinical and laboratory Standards Institute. 29th edn. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, 2019
- Colony PCR for rapid detection of antibioticresistance genes in MRSA and enterococci.Jpn J Antibiot. 2000; 53: 422e9
- Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital.Chest. 2009; 135: 633-640
- Clinical characteristics of nursing and healthcare-associated pneumonia: a Japanese variant of healthcare-associated pneumonia.Intern Med. 2012; 51: 2537-2544
- A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug resistant pathogens to select initial empiric therapy.Clin Infect Dis. 2013; 57: 1373-1383
- Multicenter survey on hospital-acquired pneumonia and the clinical efficacy of first-line antibiotics in Japan.Intern Med. 2008; 47: 245-254
- Clinical analysis of patients requiring long-term mechanical ventilation of over three months: ventilator-associated pneumonia as a primary complication.Intern Med. 2003; 42: 25-32
Japan Nosocomial Infections Surveillance, Ministry of Health, Labour and Welfare, Japan, https://janis.mhlw.go.jp/english/report/index.html [accessed 9 November 2022].
- Antimicrobial susceptibility and molecular characteristics of 857 methicillin-resistant Staphylococcus aureus isolates from 16 medical centers in Japan (2008-2009): nationwide survey of community-acquired and nosocomial MRSA.Diagn Microbiol Infect Dis. 2012; 72: 253-257
- Changing molecular epidemiology and characteristics of MRSA isolated from bloodstream infections: nationwide surveillance in Japan in 2019.J Antimicrob Chemother. 2022; 77: 2130-2141
- Vancomycin MIC creep progresses in methicillin-resistant Staphylococcus aureus despite the national antimicrobial stewardship campaign: single facility data in Japan.J Infect Chemother. 2022; 28: 918-922
- Practical guidelines for the management and treatment of infections caused by MRSA, 2019.in: Japanese, Japanese society of chemotherapy and the Japanese association for infectious disease. Edition. 2019 (Tokyo)https://www.chemotherapy.or.jp/uploads/files/guideline/guideline_mrsa_2019.pdf(accessed)Date accessed: November 9, 2022
- Updated clinical practice guidelines for therapeutic drug monitoring of antimicrobial agents: consensus Review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring, in Japanese, Japanese society of chemotherapy. The Japanese Society of Therapeutic Drug Monitoring, Tokyo2022
- Multiclonal expansion and high prevalence of β-lactamase-negative Haemophilus influenzae with high-level ampicillin resistance in Japan and susceptibility to quinolones.Antimicrob Agents Chemother. 2018; 62 (e00851-18)
- The third national Japanese antimicrobial susceptibility pattern surveillance program: bacterial isolates from complicated urinary tract infection patients.J Infect Chemother. 2020; 26: 418-428
- Multicenter surveillance of the epidemiology of gram-negative bacteremia in Japan.J Infect Chemother. 2020; 26: 193-198
- Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.Antimicrob Agents Chemother. 2014; 58: 654-663
- Routes of transmission of VIM-positive Pseudomonas aeruginosa in the adult intensive care unit-analysis of 9 years of surveillance at a university hospital using a mathematical model.Antimicrob Resist Infect Control. 2022; 11: 55
Article info
Publication history
Published online: May 10, 2023
Accepted:
April 16,
2023
Received in revised form:
March 22,
2023
Received:
January 19,
2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
